Sopharma AD-SofiaWAR:SPH 68 Gross Margin % is 25.27% as of Mar. 2026, which is 14% above its 10-year median of 22.16. GuruFocus rates WAR:SPH with a GF Score™ of 68/100 and a GF Value™ of zł12.97 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 116 Medical Distribution companies, Sopharma AD-Sofia ranks better than 62.07% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sopharma AD-Sofia had a gross margin of 25.27% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sopharma AD-Sofia Gross Margin % Related Terms
Sopharma AD-Sofia Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, CAH, COR: Gross Margin % Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sopharma AD-Sofia (WAR:SPH) has a Gross Margin % of 25.27% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Sopharma AD-Sofia and its competitors. This is 14% above median its historical median of 22.16. Over the past decade, Sopharma AD-Sofia's Gross Margin % has ranged from 21.11 to 25.05. According to the industry distribution chart, Sopharma AD-Sofia ranks #44 out of 116 companies in the Medical Distribution industry, placing it in the top 37.9%.
Is Sopharma AD-Sofia's Gross Margin % too high?
Sopharma AD-Sofia's current Gross Margin % of 25.27% is 14% above median its 10-year median of 22.16. Over the past 10 years, this metric has ranged from a low of 21.11 to a high of 25.05. The Medical Distribution industry median Gross Margin % is 14.90. Sopharma AD-Sofia's value of 25.27% is 69.6% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #44 out of 116 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sopharma AD-Sofia has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Gross Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #44 out of 116 companies for Gross Margin %. This puts Sopharma AD-Sofia in the upper half of its industry. The industry median Gross Margin % is 14.90. Sopharma AD-Sofia's value of 25.27% is 69.6% above this benchmark. Historically, Sopharma AD-Sofia's own Gross Margin % has ranged from 21.11 to 25.05 over the past decade. While the company's 10-year median is 22.16 vs. the industry median of 14.90, Sopharma AD-Sofia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.90, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current Gross Margin % of 25.27% is 69.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Gross Margin % is 25.27%, which is 14% above median its own 10-year median of 22.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł12.97, compared to a current price of zł7.92 — trading 38.9% below its estimated fair value. The current Gross Margin % is 25.27%, which is 14% above median its 10-year median of 22.16 and 69.6% above the Medical Distribution industry median of 14.90. Sopharma AD-Sofia's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Gross Margin % is 25.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.92 is trading 38.9% below its estimated GF Value™ of zł12.97.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Gross Margin %: 25.27% (14% above median its 10-year median of 22.16)
GF Value™: zł12.97 vs. price of zł7.92 (38.9% below fair value)
Industry Position: 69.6% above the Medical Distribution median (#44 of 116)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
68GF Score
Get the complete analysis for WAR:SPH
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
